Back to Search
RASHMI SRIDHARA, D.O.
D.O.
Internal Medicine Physician
NPI: 1639529613IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
5101022744(MI)
CMS Specialties
PrimaryINTERNAL MEDICINE
Education
ARIZONA COLLEGE OF OSTEOPATHIC MEDICINE MID WESTERN UNIVERSITY
Class of 2016
Research & Publications (20)
Evaluation of health-related quality-of-life measures in oncology drug product applications: issues and concerns.
PMID 15027498·J Biopharm Stat·2004
8-other
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
PMID 19144678·Oncologist·2009
6-review
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
PMID 18849320·Oncologist·2008
3-trial
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
PMID 18765523·Clin Cancer Res·2008
8-other
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
PMID 18628451·Clin Cancer Res·2008
4-observational
Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues.
PMID 18285437·Stat Methods Med Res·2008
8-other
Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
PMID 18922829·Oncologist·2008
4-observational
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
PMID 18223208·Clin Cancer Res·2008
8-other
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
PMID 17438089·Clin Cancer Res·2007
7-preclinical
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
PMID 18077994·Oncology (Williston Park)·2007
3-trial
Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
PMID 17951228·J Natl Cancer Inst Monogr·2007
8-other
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
PMID 18247017·Oncology (Williston Park)·2007
3-trial
Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
PMID 17000665·Clin Cancer Res·2006
7-preclinical
Sorafenib for the treatment of advanced renal cell carcinoma.
PMID 17189398·Clin Cancer Res·2006
6-review
Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer.
PMID 17112001·Oncology (Williston Park)·2006
4-observational
United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.
PMID 16707588·Clin Cancer Res·2006
8-other
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
PMID 16166415·Clin Cancer Res·2005
3-trial
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
PMID 16115902·Clin Cancer Res·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11885 E 12 MILE RD STE 300A
WARREN, MI 48093 - Phone
- (586) 582-6630
Quick Facts
- NPI
- 1639529613
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 10
- Publications
- 20
Are you this provider?
Claim Your Profile